Why are the 1993 financials presented on a combined basis, and how does that affect comparability?

The February 1994 merger with HCA and the 1993 Galen merger were both accounted for as poolings of interests, so the statements retroactively combine all three companies for every period shown. The reported figures therefore reflect the full combined business rather than the historical results of Columbia alone, and prior-year figures have been restated accordingly.

What drove the large swing in net income from 1992 to 1993?

The 1992 result of $165 million included a $394 million pretax charge for divesting psychiatric hospitals and a $138 million Spinoff-related charge, along with a $180 million net loss in discontinued health plan operations. 1993 net income of $507 million was far cleaner, though it still absorbed $151 million in Galen Merger costs and an $84 million extraordinary loss on debt refinancing.

How much tax exposure does the company face from the IRS disputes?

Columbia/HCA is contesting several IRS assertions tied to HCA's pre-merger years. The disclosed potential additional liabilities include about $110 million in taxes plus $432 million in interest on the cash-method issue and $113 million in taxes plus $139 million in interest on hospital acquisitions. Management says the ultimate resolution is not expected to have a material adverse effect, though these amounts are large relative to annual net income.

Is the company's debt burden improving?

Yes, in several respects. Long-term debt was roughly flat at $3.3 billion, but interest expense dropped to $321 million from $401 million in 1992 and $597 million in 1991, and the company refinanced $787 million of high-rate debt during 1993. Subsequent to year-end, it set up $3 billion in revolving credit facilities and continued refinancing, though management expected a roughly $80 million first-quarter 1994 loss from those refinancings.

HCA 10-K FY1993 Annual Report — Revenue, Net Income, EPS

01—Abstract

Summary

Summary of the 10-K/A filed July 7, 1994. Cited figures are marked; the original filing is the authoritative source.

Columbia/HCA Healthcare Corporation's amended 10-K/A-1 (fiscal year ended December 31, 1993) restates the company's historical financials following its February 10, 1994 merger with HCA-Hospital Corporation of America, accounted for as a pooling of interests.

Because of this, the figures reflect the combined operations of Columbia, HCA, and Galen for all periods presented. Combined 1993 revenues were $10.25 billion^a (up 3% from $9.93 billion in 1992), and net income was $507 million, or $1.50 per share, compared with $165 million in 1992. The 1992 result was depressed by large non-recurring charges and a discontinued health plan business, so the year-over-year improvement is partly a comparison effect.

Income from continuing operations rose sharply to $575 million^b from $239 million, though 1993 still carried $151 million of Galen Merger-related non-recurring charges and an $84 million after-tax extraordinary loss on debt refinancing. Balance sheet and cash flow metrics were steady. Total assets were $10.2 billion, long-term debt was $3.3 billion, and stockholders' equity was $3.5 billion.

Cash flow from continuing operations was $1.30 billion^c, while capital expenditures were $836 million, leaving meaningful free cash flow. Management has been reducing interest costs, with interest expense falling to $321 million from $401 million in 1992 and $597 million in 1991, and the company established $3 billion in new revolving credit facilities in February 1994. Investors should weigh several risk factors.

The IRS is contesting numerous tax deficiencies from HCA's pre-merger years, with the company estimating potential additional taxes and interest in the range of several hundred million dollars if the IRS prevails. Professional liability reserves stand at $817 million^d, and federal regulators are reviewing financial arrangements with physicians at two psychiatric hospitals. Note that this filing is an amendment limited to Item 8 (financial statements) and does not include the full business discussion, MD&A, or risk factors found in the original 10-K.

02—Key points

Key Highlights

Revenues of $10.25 billion in 1993, up 3% from $9.93 billion in 1992, reflecting the combined Columbia, HCA, and Galen operations under pooling-of-interests accounting.
Net income of $507 million ($1.50 per share) in 1993, versus $165 million ($0.50 per share) in 1992, which was burdened by large non-recurring charges.
Income from continuing operations more than doubled to $575 million from $239 million, though 1993 included $151 million in Galen Merger-related non-recurring charges.
Interest expense fell 20% to $321 million from $401 million, following refinancing activity that reduced high-rate debt and generated an $84 million after-tax extraordinary loss.
Operating cash flow from continuing operations of $1.30 billion, against capital expenditures of $836 million, supporting ongoing facility investment.
Total assets of $10.2 billion, long-term debt of $3.3 billion, and stockholders' equity of $3.5 billion at December 31, 1993.
Material contingencies include IRS challenges to HCA's pre-merger tax returns (potential additional taxes and interest in the hundreds of millions) and federal regulatory review of physician financial arrangements at two psychiatric hospitals.

03—Questions

Frequently Asked Questions

Why are the 1993 financials presented on a combined basis, and how does that affect comparability?
The February 1994 merger with HCA and the 1993 Galen merger were both accounted for as poolings of interests, so the statements retroactively combine all three companies for every period shown. The reported figures therefore reflect the full combined business rather than the historical results of Columbia alone, and prior-year figures have been restated accordingly.
What drove the large swing in net income from 1992 to 1993?
The 1992 result of $165 million included a $394 million pretax charge for divesting psychiatric hospitals and a $138 million Spinoff-related charge, along with a $180 million net loss in discontinued health plan operations. 1993 net income of $507 million was far cleaner, though it still absorbed $151 million in Galen Merger costs and an $84 million extraordinary loss on debt refinancing.
How much tax exposure does the company face from the IRS disputes?
Columbia/HCA is contesting several IRS assertions tied to HCA's pre-merger years. The disclosed potential additional liabilities include about $110 million in taxes plus $432 million in interest on the cash-method issue and $113 million in taxes plus $139 million in interest on hospital acquisitions. Management says the ultimate resolution is not expected to have a material adverse effect, though these amounts are large relative to annual net income.
Is the company's debt burden improving?
Yes, in several respects. Long-term debt was roughly flat at $3.3 billion, but interest expense dropped to $321 million from $401 million in 1992 and $597 million in 1991, and the company refinanced $787 million of high-rate debt during 1993. Subsequent to year-end, it set up $3 billion in revolving credit facilities and continued refinancing, though management expected a roughly $80 million first-quarter 1994 loss from those refinancings.

04—Continue

← View all 10-K filings